Dr. Hofmeister is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1365 Clifton Rd
Rm 4122, 4th floor, Emory Clinic Building B
Atlanta, GA 30322Phone+1 404-778-1900Fax+1 404-778-1215- Is this information wrong?
Summary
- I am a hematologist specializing in patients with multiple myeloma.
Education & Training
Ohio State UniversityMPH, Clinical Investigation, 2009 - 2012
Loyola University Medical CenterFellowship, Hematopoietic Stem Cell Transplantation, 2005 - 2006- Loyola University Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
- Loyola University Medical CenterResidency, Internal Medicine, 1999 - 2002
Ohio State University College of MedicineClass of 1999
Brown UniversityBS, Biochemistry and Molecular Biology, 1991 - 1995
Certifications & Licensure
GA State Medical License 2017 - 2025
LA State Medical License 2020 - 2022
NC State Medical License 2020 - 2022
AL State Medical License 2020 - 2020
OH State Medical License 2006 - 2018
IL State Medical License 1999 - 2008- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Business First’s Forty Under 40 Award Columbus Dispatch, 2011
- Early Career Achievement Award The Ohio State University College of Medicine, 2011
- Imagine MMORE Award MMORE (Multiple Myeloma Opportunities for Research & Education), 2009
- Join now to see all
Clinical Trials
- Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma Start of enrollment: 2004 Jul 01
- Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease Start of enrollment: 2003 Jul 01
- Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation Start of enrollment: 2004 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience.Scott, S., Marin, E., Maples, K., Joseph, N., Hofmeister, C., Gupta, V., Kaufman, J., Lonial, S., Nooka, A., Dhodapkar, M.> ;Blood Cancer Journal. 2023 Dec 20
- Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.Alessandro Canella, Hector Cordero Nieves, Douglas W Sborov, Luciano Cascione, Hanna S Radomska, Emily Smith, Andrew Stiff, Jessica Consiglio, Enrico Caserta, Lara Riz...> ;Oncotarget. 2023 Sep 25
- Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity.Alberto Moreno, Kelly Manning, Maryam I Azeem, Ajay K Nooka, Madison Ellis, Renee Julia Manalo, Jeffrey M Switchenko, Bushra Wali, Jonathan L Kaufman, Craig C Hofmeist...> ;Research Square. 2023 Sep 21
- Join now to see all
Journal Articles
- Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple MyelomaMyo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
- Evidence Does Not Support Clinically Significant Lenalidomide-CCI-779 Interaction via P-Glycoprotein ReplyHofmeister,CC; Yang,X; Phelps,MA, Journal of Clinical Oncology, 1/1/2012
- Evaluation of pulmonary infiltrates in post stem cell transplant patientsScaglione S, Hofmeister CC, Stiff PJ, Hematology, 12/1/2005
- Join now to see all
Abstracts/Posters
- Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with ...Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple MyelomaCraig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual MeetingMay 29th, 2020
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational HighlightsMarch 5th, 2020
Researchers Provide Highlights on Study into Benefits of Reolysin, Kyprolis Combo in Multiple MyelomaJanuary 31st, 2020- Join now to see all
Professional Memberships
- Member
- Member
Hospital Affiliations
Emory University HospitalAtlanta, Georgia
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
